MALAYSIA – The Malaysian government has awarded Biocon Biologics’ subsidiary a contract worth US$90 million (approximately Rs.688 crore) to supply of recombinant human (rh)-insulin brand, Insugen for the treatment of…
Read MoreMALAYSIA – The Malaysian government has awarded Biocon Biologics’ subsidiary a contract worth US$90 million (approximately Rs.688 crore) to supply of recombinant human (rh)-insulin brand, Insugen for the treatment of…
Read More